Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors.

ABSTRACT:

Background

Precision oncology has evolved from concept to clinical reality, advancing cancer treatment and drug development in the last decade. However, disparities persist in patient access to comprehensive genomic profiling and matched therapies.

Materials and methods

This was a retrospective analysis of all patients enrolled in the Vall d'Hebron Institute of Oncology (VHIO) precision medicine program (PMP) between 2014 and 2024. Tumor profiling outcomes were reviewed, focusing on actionable alterations, classified by the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT). Interpretation and therapy prioritization were standardized through regular multidisciplinary molecular tumor boards. Key performance indicators (KPIs) in

SUBMITTER: Dienstmann R 

PROVIDER: S-EPMC12639418 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature